294 related articles for article (PubMed ID: 1997328)
1. Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes.
Gourlet P; Woussen-Colle MC; Robberecht P; de Neef P; Cauvin A; Vandermeers-Piret MC; Vandermeers A; Christophe J
Eur J Biochem; 1991 Jan; 195(2):535-41. PubMed ID: 1997328
[TBL] [Abstract][Full Text] [Related]
2. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J.
Buscail L; Gourlet P; Cauvin A; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
FEBS Lett; 1990 Mar; 262(1):77-81. PubMed ID: 2156735
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist.
Robberecht P; Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers-Piret MC; Vandermeers A; Christophe J
Eur J Biochem; 1992 Jul; 207(1):239-46. PubMed ID: 1321043
[TBL] [Abstract][Full Text] [Related]
4. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.
Vandermeers A; Vandenborre S; Hou X; de Neef P; Robberecht P; Vandermeers-Piret MC; Christophe J
Eur J Biochem; 1992 Sep; 208(3):815-9. PubMed ID: 1327769
[TBL] [Abstract][Full Text] [Related]
6. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes.
Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers A; Vandermeers-Piret MC; Robberecht P; Christophe J
Biochim Biophys Acta; 1991 Jul; 1066(2):245-51. PubMed ID: 1649637
[TBL] [Abstract][Full Text] [Related]
7. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
8. PACAP and VIP stimulate enzyme secretion in rat pancreatic acini via interaction with VIP/PACAP-2 receptors: additive augmentation of CCK/carbachol-induced enzyme release.
Schmidt WE; Seebeck J; Höcker M; Schwarzhoff R; Schäfer H; Fornefeld H; Morys-Wortmann C; Fölsch UR; Creutzfeldt W
Pancreas; 1993 Jul; 8(4):476-87. PubMed ID: 8103217
[TBL] [Abstract][Full Text] [Related]
9. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide.
Gottschall PE; Tatsuno I; Miyata A; Arimura A
Endocrinology; 1990 Jul; 127(1):272-7. PubMed ID: 2361473
[TBL] [Abstract][Full Text] [Related]
10. The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK.
Cauvin A; Buscail L; Gourlet P; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
Peptides; 1990; 11(4):773-7. PubMed ID: 2172943
[TBL] [Abstract][Full Text] [Related]
11. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
12. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
13. Recognition of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide (PACAP/VIP) hybrids and related peptides by rat brain membranes.
Ando E; Nokihara K; Naruse S; Wray V
Biomed Pept Proteins Nucleic Acids; 1996; 2(2):41-6. PubMed ID: 9346825
[TBL] [Abstract][Full Text] [Related]
14. PACAP and VIP receptors in rat liver membranes.
Robberecht P; Gourlet P; Cauvin A; Buscail L; De Neef P; Arimura A; Christophe J
Am J Physiol; 1991 Jan; 260(1 Pt 1):G97-102. PubMed ID: 1846275
[TBL] [Abstract][Full Text] [Related]
15. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.
Robberecht P; Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers-Piret MC; Vandermeers A; Christophe J
Mol Pharmacol; 1992 Aug; 42(2):347-55. PubMed ID: 1325033
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a guanosine-nucleotide-binding-protein-coupled receptor for pituitary adenylate-cyclase-activating polypeptide on plasma membranes from rat brain.
Schäfer H; Schwarzhoff R; Creutzfeldt W; Schmidt WE
Eur J Biochem; 1991 Dec; 202(3):951-8. PubMed ID: 1662620
[TBL] [Abstract][Full Text] [Related]
18. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
Moody TW; Zia F; Makheja A
Peptides; 1993; 14(2):241-6. PubMed ID: 8387187
[TBL] [Abstract][Full Text] [Related]
19. Receptors for pituitary adenylate cyclase-activating peptide in human liver.
Guijarro LG; Rodriguez-Henche N; García-López E; Noguerales F; Dapena MA; Juarranz MG; Prieto JC
J Clin Endocrinol Metab; 1995 Aug; 80(8):2451-7. PubMed ID: 7629241
[TBL] [Abstract][Full Text] [Related]
20. Structural motifs of pituitary adenylate cyclase-activating polypeptide (PACAP) defining PAC1-receptor selectivity.
Schäfer H; Zheng J; Morys-Wortmann C; Fölsch UR; Schmidt WE
Regul Pept; 1999 Feb; 79(2-3):83-92. PubMed ID: 10100920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
